Showing 3591-3600 of 5693 results for "".
- Topcon Healthcare Launches IDHea to Fuel AI and Digital Health Innovation from the Eyehttps://modernod.com/news/topcon-healthcare-launches-idhea-to-fuel-ai-and-digital-health-innovation-from-the-eye/2482792/Topcon Healthcare announced the launch of the Institute of Digital Health (IDHea), an ocular data-as-a-service platform designed to accelerate AI research and digital health innovation. IDHea is designed to provide fast and secure access to unique real-world and clinical trial datasets,
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Partner to Launch New Medical Technology Companyhttps://modernod.com/news/moorfields-eye-hospital-ucl-institute-of-ophthalmology-and-topcon-partner-to-launch-new-medical-technology-company/2482786/Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Healthcare announced the launch of Cascader Limited, a new medical technology company that aims to transform the detection and management of eye disease through artificial intelligence (AI). Cascade
- Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMDhttps://modernod.com/news/chengdu-origen-and-vanotech-announce-first-patient-dosed-in-phase-1-trial-of-gene-therapy-for-wet-amd/2482781/Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-lab
- Oculis to Present Its Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/oculis-to-present-its-innovative-late-stage-pipeline-candidates-at-upcoming-ophthalmology-conferences/2482774/Oculis Holding AG announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Stud
- datosX and Topcon Healthcare Forge Strategic Partnership to Accelerate Digital Health Innovationhttps://modernod.com/news/datosx-and-topcon-healthcare-forge-strategic-partnership-to-accelerate-digital-health-innovation/2482770/datosX Digital Health Labs, a provider of digital health technology (DHT) testing and real-world validation for DHTs, announced an investment and strategic partnership with Topcon Healthcare. Financial terms of the deal were not disclosed. </
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Regeneron to Present 27 New Eylea HD Injection 8 mg Abstracts and Presentations at ARVOhttps://modernod.com/news/regeneron-to-present-27-new-eylea-hd-injection-8-mg-abstracts-and-presentations-at-arvo/2482766/Regeneron announced the upcoming presentation of 27 abstracts, including eight oral presentations on Eylea HD (aflibercept) Injection 8 mg in wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR). Among the new results and analyses are initia
- Alcon Launches UNITY VCS and UNITY CS for for Vitreoretinal and Cataract Surgeryhttps://modernod.com/news/alcon-launches-unity-vcs-and-unity-cs-for-for-vitreoretinal-and-cataract-surgery/2482763/Alcon announced the launch of the UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS). The platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). It is designed to deliver superior efficiency for vit
- University of Cincinnati Study Finds Fear of Vision Loss is a Barrier to Cataract Surgeryhttps://modernod.com/news/university-of-cincinnati-study-finds-fear-of-vision-loss-is-a-barrier-to-cataract-surgery/2482761/Fear of vision loss, particularly among patients who have a visually significant cataract in only one eye, may deter some from undergoing cataract surgery, according to a new study from the Department of Ophthalmology at the University of Cincinnati (UC). The study,